Loading…
Glycated Hemoglobin Level Goal Achievement in Adults With Type 2 Diabetes in Canada: Still Room for Improvement
To describe the clinical histories and management of adults with type 2 diabetes who were not reaching their target glycated hemoglobin (A1C) levels and to identify barriers to achieving therapeutic goals. Practice assessment surveys and practice audits were completed by 88 primary care physicians (...
Saved in:
Published in: | Canadian journal of diabetes 2019-08, Vol.43 (6), p.384-391 |
---|---|
Main Authors: | , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c356t-20c492fdfc100a1660f028f0c0a3e977cabf5d0ad7fca931cb2068fb6aa661663 |
---|---|
cites | cdi_FETCH-LOGICAL-c356t-20c492fdfc100a1660f028f0c0a3e977cabf5d0ad7fca931cb2068fb6aa661663 |
container_end_page | 391 |
container_issue | 6 |
container_start_page | 384 |
container_title | Canadian journal of diabetes |
container_volume | 43 |
creator | Leiter, Lawrence A. Cheng, Alice Y.Y. Ekoé, Jean-Marie Goldenberg, Ronald M. Harris, Stewart B. Hramiak, Irene M. Khunti, Kamlesh Lin, Peter J. Richard, Jean-François Senior, Peter A. Yale, Jean-François Goldin, Lianne Tan, Mary K. Langer, Anatoly |
description | To describe the clinical histories and management of adults with type 2 diabetes who were not reaching their target glycated hemoglobin (A1C) levels and to identify barriers to achieving therapeutic goals.
Practice assessment surveys and practice audits were completed by 88 primary care physicians (PCPs) in the Diabetes Mellitus Assessment of Clinical managemenT In ONtario (DM-ACTION) program and by 56 diabetes specialists in the Diabetes Mellitus IMproving PAtient Care in our communiTies (DM-IMPACT) program. The DM-ACTION audit analyzed data from 1,173 adults with A1C levels ≥7.3% who were not prescribed insulin; the DM-IMPACT audit included 135 individuals with similar characteristics.
Most PCPs (92%) and specialists (88%) stated that they typically recommend A1C levels of ≤7.0%; more than 90% indicated that they adjusted antihyperglycemic therapy within 3 months if suboptimal A1C targets endured. Among the DM-ACTION patients, the median A1C level was 7.8%; the median time between the last 2 A1C tests was 5 months; 58% were taking ≤2 noninsulin antihyperglycemic agents; and adjustment of glucose-lowering therapy was noted for only 56%. The corresponding values for the DM-IMPACT patients were 8.0%, 4 months, 43% and 68%, respectively. PCPs and specialists attributed patients' factors and patients' adherence as primary causes of poor achievement of guideline-recommended targets. PCPs perceived patients' factors as the predominant barrier to optimizing care, but the specialists believed that therapeutic inertia stems from a wide range and a varied combination of patient-centric factors.
Type 2 diabetes remains a health-care challenge in Canada and globally. Primary care physicians and specialists attributed patients' factors as principal obstacles to optimal diabetes management. However, physician-associated therapeutic inertia may also be an important barrier to unmet therapeutic goals.
Décrire les antécédents cliniques et la prise en charge des adultes atteints du diabète de type 2 qui n'avaient pas atteint leurs valeurs cibles d'hémoglobine glyquée (A1c) et déterminer les obstacles à l'atteinte des objectifs thérapeutiques.
Quatre-vingt-huit médecins en soins de santé primaires (MSSP) du programme DM-ACTION (Diabetes Mellitus Assessment of Clinical managemenT In ONtario) et 56 spécialistes du diabète du programme DM-IMPACT (Diabetes Mellitus IMproving PAtient Care in our communiTies) ont rempli les enquêtes d'évaluation des pratiques et les audits de pra |
doi_str_mv | 10.1016/j.jcjd.2018.10.005 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2157656933</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1499267118303708</els_id><sourcerecordid>2157656933</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-20c492fdfc100a1660f028f0c0a3e977cabf5d0ad7fca931cb2068fb6aa661663</originalsourceid><addsrcrecordid>eNp9kMGO0zAQhi0EYsvCC3BAPnJJGTu1kyAuVRe6K1VCgkUcLcces46cuMTuSn17HHXhyGk0M9_8lj9C3jJYM2Dyw7AezGDXHFhbBmsA8YyseC14VbcbeE5WbNN1FZcNuyKvUhoKAA3rXpKrGoTYdK1YkbgPZ6MzWnqLY_wVYu8nesBHDHQfdaBb8-BLN-KUadls7SnkRH_6_EDvz0eknN543WPGtKx3etJWf6Tfsw-BfotxpC7O9G48zvES8pq8cDokfPNUr8mPL5_vd7fV4ev-brc9VKYWMlcczKbjzjrDADSTEhzw1oEBXWPXNEb3TljQtnFGdzUzPQfZul5qLWXB62vy_pJbXv59wpTV6JPBEPSE8ZQUZ6KRQnZ1XVB-Qc0cU5rRqePsRz2fFQO1iFaDWkSrRfQyKx7L0bun_FM_ov138tdsAT5dACy_fPQ4q2Q8Tgatn9FkZaP_X_4fAhaO2g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2157656933</pqid></control><display><type>article</type><title>Glycated Hemoglobin Level Goal Achievement in Adults With Type 2 Diabetes in Canada: Still Room for Improvement</title><source>ScienceDirect Freedom Collection</source><creator>Leiter, Lawrence A. ; Cheng, Alice Y.Y. ; Ekoé, Jean-Marie ; Goldenberg, Ronald M. ; Harris, Stewart B. ; Hramiak, Irene M. ; Khunti, Kamlesh ; Lin, Peter J. ; Richard, Jean-François ; Senior, Peter A. ; Yale, Jean-François ; Goldin, Lianne ; Tan, Mary K. ; Langer, Anatoly</creator><creatorcontrib>Leiter, Lawrence A. ; Cheng, Alice Y.Y. ; Ekoé, Jean-Marie ; Goldenberg, Ronald M. ; Harris, Stewart B. ; Hramiak, Irene M. ; Khunti, Kamlesh ; Lin, Peter J. ; Richard, Jean-François ; Senior, Peter A. ; Yale, Jean-François ; Goldin, Lianne ; Tan, Mary K. ; Langer, Anatoly</creatorcontrib><description>To describe the clinical histories and management of adults with type 2 diabetes who were not reaching their target glycated hemoglobin (A1C) levels and to identify barriers to achieving therapeutic goals.
Practice assessment surveys and practice audits were completed by 88 primary care physicians (PCPs) in the Diabetes Mellitus Assessment of Clinical managemenT In ONtario (DM-ACTION) program and by 56 diabetes specialists in the Diabetes Mellitus IMproving PAtient Care in our communiTies (DM-IMPACT) program. The DM-ACTION audit analyzed data from 1,173 adults with A1C levels ≥7.3% who were not prescribed insulin; the DM-IMPACT audit included 135 individuals with similar characteristics.
Most PCPs (92%) and specialists (88%) stated that they typically recommend A1C levels of ≤7.0%; more than 90% indicated that they adjusted antihyperglycemic therapy within 3 months if suboptimal A1C targets endured. Among the DM-ACTION patients, the median A1C level was 7.8%; the median time between the last 2 A1C tests was 5 months; 58% were taking ≤2 noninsulin antihyperglycemic agents; and adjustment of glucose-lowering therapy was noted for only 56%. The corresponding values for the DM-IMPACT patients were 8.0%, 4 months, 43% and 68%, respectively. PCPs and specialists attributed patients' factors and patients' adherence as primary causes of poor achievement of guideline-recommended targets. PCPs perceived patients' factors as the predominant barrier to optimizing care, but the specialists believed that therapeutic inertia stems from a wide range and a varied combination of patient-centric factors.
Type 2 diabetes remains a health-care challenge in Canada and globally. Primary care physicians and specialists attributed patients' factors as principal obstacles to optimal diabetes management. However, physician-associated therapeutic inertia may also be an important barrier to unmet therapeutic goals.
Décrire les antécédents cliniques et la prise en charge des adultes atteints du diabète de type 2 qui n'avaient pas atteint leurs valeurs cibles d'hémoglobine glyquée (A1c) et déterminer les obstacles à l'atteinte des objectifs thérapeutiques.
Quatre-vingt-huit médecins en soins de santé primaires (MSSP) du programme DM-ACTION (Diabetes Mellitus Assessment of Clinical managemenT In ONtario) et 56 spécialistes du diabète du programme DM-IMPACT (Diabetes Mellitus IMproving PAtient Care in our communiTies) ont rempli les enquêtes d'évaluation des pratiques et les audits de pratique. L'audit du DM-ACTION a permis d'analyser les données de 1173 adultes qui avaient des concentrations d'A1c ≥ 7,3 % et qui ne s'étaient pas fait prescrire d'insuline; l'audit du DM-IMPACT portait sur 135 individus qui avaient des caractéristiques similaires.
La plupart des MSSP (92 %) et des spécialistes (88 %) ont déclaré avoir habituellement recommandé des concentrations d'A1C ≤ 7,0 %; plus de 90 % ont indiqué avoir ajusté le traitement antihyperglycémique dans les 3 mois si les valeurs cibles sous-optimales de l'A1c s'étaient maintenues. Parmi les patients du DM-ACTION, la concentration médiane d'A1c était de 7,8 %; le temps médian entre les 2 dernières épreuves d'A1c était de 5 mois; 58 % prenaient ≤2 antihyperglycémiants non insuliniques; l'ajustement du traitement hypoglycémiant a été noté chez seulement 56 % des individus. Les valeurs correspondantes chez les patients du DM-IMPACT étaient respectivement de 8,0 %, de 4 mois, de 43 % et de 68 %. Les MSSP et les spécialistes ont considéré que les facteurs liés aux patients et à l'observance des patients étaient les principales causes de la faible atteinte des valeurs cibles recommandées par les lignes directrices. Les MSSP ont perçu les facteurs liés aux patients comme l'obstacle le plus important à l'optimisation des soins, mais les spécialistes ont cru que l'inertie thérapeutique découlait d'un large éventail et d'une combinaison variée de facteurs axés sur le patient.
Le diabète de type 2 reste un problème important pour les soins de santé au Canada et dans le monde entier. Les MSSP et les spécialistes ont considéré que les principaux obstacles à la prise en charge optimale du diabète étaient attribuables aux facteurs liés aux patients. Toutefois, l'inertie thérapeutique des médecins peut également être un obstacle important à la non-atteinte des objectifs thérapeutiques.</description><identifier>ISSN: 1499-2671</identifier><identifier>EISSN: 2352-3840</identifier><identifier>DOI: 10.1016/j.jcjd.2018.10.005</identifier><identifier>PMID: 30554985</identifier><language>eng</language><publisher>Canada: Elsevier Inc</publisher><subject>Adult ; Biomarkers - analysis ; Blood Glucose - analysis ; Diabetes Mellitus, Type 2 - metabolism ; Diabetes Mellitus, Type 2 - prevention & control ; diabète de type 2 ; Disease Management ; Female ; Follow-Up Studies ; Glycated Hemoglobin A - analysis ; Humans ; Hypoglycemic Agents - therapeutic use ; inertie thérapeutique ; Male ; Medication Adherence - statistics & numerical data ; Middle Aged ; Needs Assessment ; Patient Care - methods ; Patient Care - standards ; Physicians, Primary Care - standards ; Practice Guidelines as Topic - standards ; primary care ; Prognosis ; soins de santé primaires ; specialist ; Specialization - statistics & numerical data ; spécialiste ; Surveys and Questionnaires ; therapeutic inertia ; type 2 diabetes</subject><ispartof>Canadian journal of diabetes, 2019-08, Vol.43 (6), p.384-391</ispartof><rights>2018 Canadian Diabetes Association</rights><rights>Copyright © 2018 Canadian Diabetes Association. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-20c492fdfc100a1660f028f0c0a3e977cabf5d0ad7fca931cb2068fb6aa661663</citedby><cites>FETCH-LOGICAL-c356t-20c492fdfc100a1660f028f0c0a3e977cabf5d0ad7fca931cb2068fb6aa661663</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30554985$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Leiter, Lawrence A.</creatorcontrib><creatorcontrib>Cheng, Alice Y.Y.</creatorcontrib><creatorcontrib>Ekoé, Jean-Marie</creatorcontrib><creatorcontrib>Goldenberg, Ronald M.</creatorcontrib><creatorcontrib>Harris, Stewart B.</creatorcontrib><creatorcontrib>Hramiak, Irene M.</creatorcontrib><creatorcontrib>Khunti, Kamlesh</creatorcontrib><creatorcontrib>Lin, Peter J.</creatorcontrib><creatorcontrib>Richard, Jean-François</creatorcontrib><creatorcontrib>Senior, Peter A.</creatorcontrib><creatorcontrib>Yale, Jean-François</creatorcontrib><creatorcontrib>Goldin, Lianne</creatorcontrib><creatorcontrib>Tan, Mary K.</creatorcontrib><creatorcontrib>Langer, Anatoly</creatorcontrib><title>Glycated Hemoglobin Level Goal Achievement in Adults With Type 2 Diabetes in Canada: Still Room for Improvement</title><title>Canadian journal of diabetes</title><addtitle>Can J Diabetes</addtitle><description>To describe the clinical histories and management of adults with type 2 diabetes who were not reaching their target glycated hemoglobin (A1C) levels and to identify barriers to achieving therapeutic goals.
Practice assessment surveys and practice audits were completed by 88 primary care physicians (PCPs) in the Diabetes Mellitus Assessment of Clinical managemenT In ONtario (DM-ACTION) program and by 56 diabetes specialists in the Diabetes Mellitus IMproving PAtient Care in our communiTies (DM-IMPACT) program. The DM-ACTION audit analyzed data from 1,173 adults with A1C levels ≥7.3% who were not prescribed insulin; the DM-IMPACT audit included 135 individuals with similar characteristics.
Most PCPs (92%) and specialists (88%) stated that they typically recommend A1C levels of ≤7.0%; more than 90% indicated that they adjusted antihyperglycemic therapy within 3 months if suboptimal A1C targets endured. Among the DM-ACTION patients, the median A1C level was 7.8%; the median time between the last 2 A1C tests was 5 months; 58% were taking ≤2 noninsulin antihyperglycemic agents; and adjustment of glucose-lowering therapy was noted for only 56%. The corresponding values for the DM-IMPACT patients were 8.0%, 4 months, 43% and 68%, respectively. PCPs and specialists attributed patients' factors and patients' adherence as primary causes of poor achievement of guideline-recommended targets. PCPs perceived patients' factors as the predominant barrier to optimizing care, but the specialists believed that therapeutic inertia stems from a wide range and a varied combination of patient-centric factors.
Type 2 diabetes remains a health-care challenge in Canada and globally. Primary care physicians and specialists attributed patients' factors as principal obstacles to optimal diabetes management. However, physician-associated therapeutic inertia may also be an important barrier to unmet therapeutic goals.
Décrire les antécédents cliniques et la prise en charge des adultes atteints du diabète de type 2 qui n'avaient pas atteint leurs valeurs cibles d'hémoglobine glyquée (A1c) et déterminer les obstacles à l'atteinte des objectifs thérapeutiques.
Quatre-vingt-huit médecins en soins de santé primaires (MSSP) du programme DM-ACTION (Diabetes Mellitus Assessment of Clinical managemenT In ONtario) et 56 spécialistes du diabète du programme DM-IMPACT (Diabetes Mellitus IMproving PAtient Care in our communiTies) ont rempli les enquêtes d'évaluation des pratiques et les audits de pratique. L'audit du DM-ACTION a permis d'analyser les données de 1173 adultes qui avaient des concentrations d'A1c ≥ 7,3 % et qui ne s'étaient pas fait prescrire d'insuline; l'audit du DM-IMPACT portait sur 135 individus qui avaient des caractéristiques similaires.
La plupart des MSSP (92 %) et des spécialistes (88 %) ont déclaré avoir habituellement recommandé des concentrations d'A1C ≤ 7,0 %; plus de 90 % ont indiqué avoir ajusté le traitement antihyperglycémique dans les 3 mois si les valeurs cibles sous-optimales de l'A1c s'étaient maintenues. Parmi les patients du DM-ACTION, la concentration médiane d'A1c était de 7,8 %; le temps médian entre les 2 dernières épreuves d'A1c était de 5 mois; 58 % prenaient ≤2 antihyperglycémiants non insuliniques; l'ajustement du traitement hypoglycémiant a été noté chez seulement 56 % des individus. Les valeurs correspondantes chez les patients du DM-IMPACT étaient respectivement de 8,0 %, de 4 mois, de 43 % et de 68 %. Les MSSP et les spécialistes ont considéré que les facteurs liés aux patients et à l'observance des patients étaient les principales causes de la faible atteinte des valeurs cibles recommandées par les lignes directrices. Les MSSP ont perçu les facteurs liés aux patients comme l'obstacle le plus important à l'optimisation des soins, mais les spécialistes ont cru que l'inertie thérapeutique découlait d'un large éventail et d'une combinaison variée de facteurs axés sur le patient.
Le diabète de type 2 reste un problème important pour les soins de santé au Canada et dans le monde entier. Les MSSP et les spécialistes ont considéré que les principaux obstacles à la prise en charge optimale du diabète étaient attribuables aux facteurs liés aux patients. Toutefois, l'inertie thérapeutique des médecins peut également être un obstacle important à la non-atteinte des objectifs thérapeutiques.</description><subject>Adult</subject><subject>Biomarkers - analysis</subject><subject>Blood Glucose - analysis</subject><subject>Diabetes Mellitus, Type 2 - metabolism</subject><subject>Diabetes Mellitus, Type 2 - prevention & control</subject><subject>diabète de type 2</subject><subject>Disease Management</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Glycated Hemoglobin A - analysis</subject><subject>Humans</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>inertie thérapeutique</subject><subject>Male</subject><subject>Medication Adherence - statistics & numerical data</subject><subject>Middle Aged</subject><subject>Needs Assessment</subject><subject>Patient Care - methods</subject><subject>Patient Care - standards</subject><subject>Physicians, Primary Care - standards</subject><subject>Practice Guidelines as Topic - standards</subject><subject>primary care</subject><subject>Prognosis</subject><subject>soins de santé primaires</subject><subject>specialist</subject><subject>Specialization - statistics & numerical data</subject><subject>spécialiste</subject><subject>Surveys and Questionnaires</subject><subject>therapeutic inertia</subject><subject>type 2 diabetes</subject><issn>1499-2671</issn><issn>2352-3840</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp9kMGO0zAQhi0EYsvCC3BAPnJJGTu1kyAuVRe6K1VCgkUcLcces46cuMTuSn17HHXhyGk0M9_8lj9C3jJYM2Dyw7AezGDXHFhbBmsA8YyseC14VbcbeE5WbNN1FZcNuyKvUhoKAA3rXpKrGoTYdK1YkbgPZ6MzWnqLY_wVYu8nesBHDHQfdaBb8-BLN-KUadls7SnkRH_6_EDvz0eknN543WPGtKx3etJWf6Tfsw-BfotxpC7O9G48zvES8pq8cDokfPNUr8mPL5_vd7fV4ev-brc9VKYWMlcczKbjzjrDADSTEhzw1oEBXWPXNEb3TljQtnFGdzUzPQfZul5qLWXB62vy_pJbXv59wpTV6JPBEPSE8ZQUZ6KRQnZ1XVB-Qc0cU5rRqePsRz2fFQO1iFaDWkSrRfQyKx7L0bun_FM_ov138tdsAT5dACy_fPQ4q2Q8Tgatn9FkZaP_X_4fAhaO2g</recordid><startdate>201908</startdate><enddate>201908</enddate><creator>Leiter, Lawrence A.</creator><creator>Cheng, Alice Y.Y.</creator><creator>Ekoé, Jean-Marie</creator><creator>Goldenberg, Ronald M.</creator><creator>Harris, Stewart B.</creator><creator>Hramiak, Irene M.</creator><creator>Khunti, Kamlesh</creator><creator>Lin, Peter J.</creator><creator>Richard, Jean-François</creator><creator>Senior, Peter A.</creator><creator>Yale, Jean-François</creator><creator>Goldin, Lianne</creator><creator>Tan, Mary K.</creator><creator>Langer, Anatoly</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201908</creationdate><title>Glycated Hemoglobin Level Goal Achievement in Adults With Type 2 Diabetes in Canada: Still Room for Improvement</title><author>Leiter, Lawrence A. ; Cheng, Alice Y.Y. ; Ekoé, Jean-Marie ; Goldenberg, Ronald M. ; Harris, Stewart B. ; Hramiak, Irene M. ; Khunti, Kamlesh ; Lin, Peter J. ; Richard, Jean-François ; Senior, Peter A. ; Yale, Jean-François ; Goldin, Lianne ; Tan, Mary K. ; Langer, Anatoly</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-20c492fdfc100a1660f028f0c0a3e977cabf5d0ad7fca931cb2068fb6aa661663</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Biomarkers - analysis</topic><topic>Blood Glucose - analysis</topic><topic>Diabetes Mellitus, Type 2 - metabolism</topic><topic>Diabetes Mellitus, Type 2 - prevention & control</topic><topic>diabète de type 2</topic><topic>Disease Management</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Glycated Hemoglobin A - analysis</topic><topic>Humans</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>inertie thérapeutique</topic><topic>Male</topic><topic>Medication Adherence - statistics & numerical data</topic><topic>Middle Aged</topic><topic>Needs Assessment</topic><topic>Patient Care - methods</topic><topic>Patient Care - standards</topic><topic>Physicians, Primary Care - standards</topic><topic>Practice Guidelines as Topic - standards</topic><topic>primary care</topic><topic>Prognosis</topic><topic>soins de santé primaires</topic><topic>specialist</topic><topic>Specialization - statistics & numerical data</topic><topic>spécialiste</topic><topic>Surveys and Questionnaires</topic><topic>therapeutic inertia</topic><topic>type 2 diabetes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Leiter, Lawrence A.</creatorcontrib><creatorcontrib>Cheng, Alice Y.Y.</creatorcontrib><creatorcontrib>Ekoé, Jean-Marie</creatorcontrib><creatorcontrib>Goldenberg, Ronald M.</creatorcontrib><creatorcontrib>Harris, Stewart B.</creatorcontrib><creatorcontrib>Hramiak, Irene M.</creatorcontrib><creatorcontrib>Khunti, Kamlesh</creatorcontrib><creatorcontrib>Lin, Peter J.</creatorcontrib><creatorcontrib>Richard, Jean-François</creatorcontrib><creatorcontrib>Senior, Peter A.</creatorcontrib><creatorcontrib>Yale, Jean-François</creatorcontrib><creatorcontrib>Goldin, Lianne</creatorcontrib><creatorcontrib>Tan, Mary K.</creatorcontrib><creatorcontrib>Langer, Anatoly</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Canadian journal of diabetes</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Leiter, Lawrence A.</au><au>Cheng, Alice Y.Y.</au><au>Ekoé, Jean-Marie</au><au>Goldenberg, Ronald M.</au><au>Harris, Stewart B.</au><au>Hramiak, Irene M.</au><au>Khunti, Kamlesh</au><au>Lin, Peter J.</au><au>Richard, Jean-François</au><au>Senior, Peter A.</au><au>Yale, Jean-François</au><au>Goldin, Lianne</au><au>Tan, Mary K.</au><au>Langer, Anatoly</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Glycated Hemoglobin Level Goal Achievement in Adults With Type 2 Diabetes in Canada: Still Room for Improvement</atitle><jtitle>Canadian journal of diabetes</jtitle><addtitle>Can J Diabetes</addtitle><date>2019-08</date><risdate>2019</risdate><volume>43</volume><issue>6</issue><spage>384</spage><epage>391</epage><pages>384-391</pages><issn>1499-2671</issn><eissn>2352-3840</eissn><abstract>To describe the clinical histories and management of adults with type 2 diabetes who were not reaching their target glycated hemoglobin (A1C) levels and to identify barriers to achieving therapeutic goals.
Practice assessment surveys and practice audits were completed by 88 primary care physicians (PCPs) in the Diabetes Mellitus Assessment of Clinical managemenT In ONtario (DM-ACTION) program and by 56 diabetes specialists in the Diabetes Mellitus IMproving PAtient Care in our communiTies (DM-IMPACT) program. The DM-ACTION audit analyzed data from 1,173 adults with A1C levels ≥7.3% who were not prescribed insulin; the DM-IMPACT audit included 135 individuals with similar characteristics.
Most PCPs (92%) and specialists (88%) stated that they typically recommend A1C levels of ≤7.0%; more than 90% indicated that they adjusted antihyperglycemic therapy within 3 months if suboptimal A1C targets endured. Among the DM-ACTION patients, the median A1C level was 7.8%; the median time between the last 2 A1C tests was 5 months; 58% were taking ≤2 noninsulin antihyperglycemic agents; and adjustment of glucose-lowering therapy was noted for only 56%. The corresponding values for the DM-IMPACT patients were 8.0%, 4 months, 43% and 68%, respectively. PCPs and specialists attributed patients' factors and patients' adherence as primary causes of poor achievement of guideline-recommended targets. PCPs perceived patients' factors as the predominant barrier to optimizing care, but the specialists believed that therapeutic inertia stems from a wide range and a varied combination of patient-centric factors.
Type 2 diabetes remains a health-care challenge in Canada and globally. Primary care physicians and specialists attributed patients' factors as principal obstacles to optimal diabetes management. However, physician-associated therapeutic inertia may also be an important barrier to unmet therapeutic goals.
Décrire les antécédents cliniques et la prise en charge des adultes atteints du diabète de type 2 qui n'avaient pas atteint leurs valeurs cibles d'hémoglobine glyquée (A1c) et déterminer les obstacles à l'atteinte des objectifs thérapeutiques.
Quatre-vingt-huit médecins en soins de santé primaires (MSSP) du programme DM-ACTION (Diabetes Mellitus Assessment of Clinical managemenT In ONtario) et 56 spécialistes du diabète du programme DM-IMPACT (Diabetes Mellitus IMproving PAtient Care in our communiTies) ont rempli les enquêtes d'évaluation des pratiques et les audits de pratique. L'audit du DM-ACTION a permis d'analyser les données de 1173 adultes qui avaient des concentrations d'A1c ≥ 7,3 % et qui ne s'étaient pas fait prescrire d'insuline; l'audit du DM-IMPACT portait sur 135 individus qui avaient des caractéristiques similaires.
La plupart des MSSP (92 %) et des spécialistes (88 %) ont déclaré avoir habituellement recommandé des concentrations d'A1C ≤ 7,0 %; plus de 90 % ont indiqué avoir ajusté le traitement antihyperglycémique dans les 3 mois si les valeurs cibles sous-optimales de l'A1c s'étaient maintenues. Parmi les patients du DM-ACTION, la concentration médiane d'A1c était de 7,8 %; le temps médian entre les 2 dernières épreuves d'A1c était de 5 mois; 58 % prenaient ≤2 antihyperglycémiants non insuliniques; l'ajustement du traitement hypoglycémiant a été noté chez seulement 56 % des individus. Les valeurs correspondantes chez les patients du DM-IMPACT étaient respectivement de 8,0 %, de 4 mois, de 43 % et de 68 %. Les MSSP et les spécialistes ont considéré que les facteurs liés aux patients et à l'observance des patients étaient les principales causes de la faible atteinte des valeurs cibles recommandées par les lignes directrices. Les MSSP ont perçu les facteurs liés aux patients comme l'obstacle le plus important à l'optimisation des soins, mais les spécialistes ont cru que l'inertie thérapeutique découlait d'un large éventail et d'une combinaison variée de facteurs axés sur le patient.
Le diabète de type 2 reste un problème important pour les soins de santé au Canada et dans le monde entier. Les MSSP et les spécialistes ont considéré que les principaux obstacles à la prise en charge optimale du diabète étaient attribuables aux facteurs liés aux patients. Toutefois, l'inertie thérapeutique des médecins peut également être un obstacle important à la non-atteinte des objectifs thérapeutiques.</abstract><cop>Canada</cop><pub>Elsevier Inc</pub><pmid>30554985</pmid><doi>10.1016/j.jcjd.2018.10.005</doi><tpages>8</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1499-2671 |
ispartof | Canadian journal of diabetes, 2019-08, Vol.43 (6), p.384-391 |
issn | 1499-2671 2352-3840 |
language | eng |
recordid | cdi_proquest_miscellaneous_2157656933 |
source | ScienceDirect Freedom Collection |
subjects | Adult Biomarkers - analysis Blood Glucose - analysis Diabetes Mellitus, Type 2 - metabolism Diabetes Mellitus, Type 2 - prevention & control diabète de type 2 Disease Management Female Follow-Up Studies Glycated Hemoglobin A - analysis Humans Hypoglycemic Agents - therapeutic use inertie thérapeutique Male Medication Adherence - statistics & numerical data Middle Aged Needs Assessment Patient Care - methods Patient Care - standards Physicians, Primary Care - standards Practice Guidelines as Topic - standards primary care Prognosis soins de santé primaires specialist Specialization - statistics & numerical data spécialiste Surveys and Questionnaires therapeutic inertia type 2 diabetes |
title | Glycated Hemoglobin Level Goal Achievement in Adults With Type 2 Diabetes in Canada: Still Room for Improvement |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T20%3A21%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Glycated%20Hemoglobin%20Level%20Goal%20Achievement%20in%20Adults%20With%20Type%202%20Diabetes%20in%20Canada:%20Still%20Room%20for%20Improvement&rft.jtitle=Canadian%20journal%20of%20diabetes&rft.au=Leiter,%20Lawrence%20A.&rft.date=2019-08&rft.volume=43&rft.issue=6&rft.spage=384&rft.epage=391&rft.pages=384-391&rft.issn=1499-2671&rft.eissn=2352-3840&rft_id=info:doi/10.1016/j.jcjd.2018.10.005&rft_dat=%3Cproquest_cross%3E2157656933%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c356t-20c492fdfc100a1660f028f0c0a3e977cabf5d0ad7fca931cb2068fb6aa661663%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2157656933&rft_id=info:pmid/30554985&rfr_iscdi=true |